Literature DB >> 14764933

Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study.

Vallabh Janardhan1, Philip A Wolf, Carlos S Kase, Joseph M Massaro, Ralph B D'Agostino, Carl Franzblau, Peter W F Wilson.   

Abstract

BACKGROUND AND
PURPOSE: The role of anticardiolipin antibodies (aCLs) as novel risk factors for ischemic stroke and transient ischemic attacks (TIAs) has been a matter of debate. Prior cohort studies included only selected subjects, mostly men. We related serum concentrations of aCLs to incident first ischemic stroke/TIA among men and women in the Framingham Heart Study cohort and offspring.
METHODS: There were a total of 2712 women (mean age, 59.3 years) and 2262 men (mean age, 58.3 years) free of stroke/TIA at the time of their baseline examinations. An enzyme immunoassay was used to measure aCLs. Optical density of the sample serum compared with the reference serum was defined as the aCL screening ratio (aCL SR). Analyses were based on sex-specific aCL SR quartiles and individual ratios.
RESULTS: During the 11-year follow-up, 222 ischemic strokes/TIAs occurred. In multivariate analysis, after adjustment for age, prior cardiovascular disease, systolic blood pressure, diabetes, smoking, C-reactive protein, and total and high-density lipoprotein cholesterol levels, an aCL SR of >0.4 (78% of sample) was significantly associated with an increased risk of ischemic stroke/TIA for women (hazard ratio [HR], 2.6; 95% confidence interval [CI], 1.3 to 5.4; absolute risk, 3.2%, 95% CI, 2.2 to 4.3) but not in men (HR, 1.3; 95% CI, 0.7 to 2.4; absolute risk, 4.5%; 95% CI, 3.0 to 6.0). Similar results were obtained when the higher 3 aCL SR quartiles were compared with the lowest.
CONCLUSIONS: Elevated serum concentrations of aCLs, independently of other cardiovascular risk factors, significantly predict the risk of future ischemic stroke and TIA in women but not in men.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764933     DOI: 10.1161/01.STR.0000117575.48205.2D

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  24 in total

Review 1.  Intensity of warfarin coagulation in the antiphospholipid syndrome.

Authors:  Mark Crowther; Mark A Crowther
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

Review 2.  Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons.

Authors:  Eyal Muscal; Robin L Brey
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

Review 3.  Sex differences in stroke: the contribution of coagulation.

Authors:  Meaghan Roy-O'Reilly; Louise D McCullough
Journal:  Exp Neurol       Date:  2014-02-19       Impact factor: 5.330

4.  Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio.

Authors:  Colum F Amory; Steven R Levine; Robin L Brey; Mulugeta Gebregziabher; Stanley Tuhrim; Barbara C Tilley; Ann-Catherin C Simpson; Ralph L Sacco; Jay P Mohr
Journal:  Cerebrovasc Dis       Date:  2015-10-29       Impact factor: 2.762

Review 5.  Antiphospholipid syndrome and the brain in pediatric and adult patients.

Authors:  E Muscal; R L Brey
Journal:  Lupus       Date:  2010-04       Impact factor: 2.911

Review 6.  The management of stroke in antiphospholipid syndrome.

Authors:  Kessarin Panichpisal; Eduard Rozner; Steven R Levine
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

7.  Treatment of risk factors to prevent stroke.

Authors:  Junya Aoki; Ken Uchino
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

8.  Antiphospholipid antibodies, brain infarcts, and cognitive and motor decline in aging (ABICMA): design of a community-based, longitudinal, clinical-pathological study.

Authors:  Zoe Arvanitakis; Robin L Brey; Jacob H Rand; Julie A Schneider; Sue E Leurgans; Lei Yu; Aron S Buchman; Konstantinos Arfanakis; Debra A Fleischman; Patricia A Boyle; David A Bennett; Steven R Levine
Journal:  Neuroepidemiology       Date:  2012-10-24       Impact factor: 3.282

Review 9.  [Thrombophilias in patients with ischemic stroke. Indication and calculated costs for evidence-based diagnostics and treatment].

Authors:  R Weber; E Busch
Journal:  Nervenarzt       Date:  2005-02       Impact factor: 1.214

Review 10.  Systemic antiphospholipid syndrome and atherosclerosis.

Authors:  Luis J Jara; Gabriela Medina; Olga Vera-Lastra
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.